Navigation Links
Wound Management Technologies (OTCBB- WNDM) Signs Biotech Agreement With Biocure S.r.l. of Milan, Italy
Date:10/26/2009

FORT WORTH, Texas, Oct. 26 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM) through its subsidiary, Wound Care Innovations, announced today that it has reached an agreement with Biocure S.r.l. of Milan, Italy for the distribution of WNDM's patented molecular form of activated collagen, CellerateRx®.

CellerateRx is cleared by the FDA as a medical device for use on all acute and chronic wounds except for 3rd degree burns and is made in the USA. In the US alone, approximately 85% of lower extremity amputations are preceded by chronic diabetic foot wounds which lead to over 82,000 amputations annually with direct and indirect costs in the range of $2,500,000,000 to $4,920,000,000. CellerateRx targets a multi-billion dollar domestic and international wound care market with over 60% profit margins. By 2025 the Global Diabetic Market alone that potentially would be a candidate for CellerateRx is forecast to be in excess of 48,000,000 patients.

"Providing CellerateRx to the European Union through Biocure as part of our penetration of the multi-billion dollar international wound care market is an important part of WNDM's strategy. We continue to build alliances with reputable distribution networks for our advanced biotechnology and biopharmaceutical products," said Cathy Bradshaw, President of Wound Care Innovations.

Giovanni Pinamonti, President of Biocure said, "Our market feedback shows an initial target diabetic customer base in our network of over 1.5 million patients in England, Italy, France, Germany and Spain alone, without factoring in the request for burn treatment which has been very strong. CellerateRx will be an important addition in our ability to provide valuable healthcare products to the Italian market, and intend to pursue a greater European marketing program capitalizing on the strength of our network."

WMI and Biocure S.r.l. would like to take this opportunity to thank Leonardo Zangani, President of Zangani Investor Community, for all of his assistance in the course of the transaction.

In a related announcement, WNDM said it expects to shortly release preliminary details of the company's plans to leverage its existing technology and infrastructure to develop opportunities within the International Biotechnology, Genetic Engineering and Cancer Treatment markets to enhance shareholder value.

About Wound Management Technologies, Inc.

Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), with its corporate headquarters in Fort Worth, Texas, and regional offices in Ft. Lauderdale, FL is a rapidly growing provider of specialty medical products and advanced biotechnology solutions. The Company is positioned to leverage its existing technology and infrastructure to develop opportunities within the International Biotechnology, Genetic Engineering and Cancer Treatment markets. For more information on the Company please visit www.woundmanagementtechnologies.com

About Biocure S.r.l.

Biocure S.r.l. has a strong track record in the European pharmaceutical market of OTC products. Recently, they have hired corporate managers with long standing success stories from international pharmaceutical companies to ramp up their distribution channels. This has allowed the implementation of partnerships with international research groups engaged in developing proprietary and innovative biotechnology products and technologies. Biocure is based in Milan, Italy. http://www.biocure.it

"Safe Harbor" Statement:

Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

Contacts:

Product information, contact Cathy Bradshaw at 954-315-9242.

Shareholder relations, contact Lucy Singleton at 817-820-7080.

SOURCE Wound Management Technologies, Inc.


'/>"/>
SOURCE Wound Management Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Derma Sciences to Enter Phase II Development of Wound Healing Product That May Use Bodys Own Naturally Occurring Stem Cells
2. Aung FootHealth Clinics & Advanced Wound Care Center Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Trial
3. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
4. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
5. Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial
6. Wound Management Technologies, Inc. Announces Evidence Based Study
7. Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers
8. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
9. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
10. New Study Using Combination of Bioengineered Skin and Stem Cells Shows Promise in Treatment of Non-Healing Wounds
11. Glycotex Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Dec. 2, 2016 The U.S. Food and ... (empagliflozin) to reduce the risk of cardiovascular death in ... disease. "Cardiovascular disease is a leading ... mellitus," said Jean-Marc Guettier , M.D., C.M., director ... FDA,s Center for Drug Evaluation and Research. "Availability of ...
(Date:12/2/2016)... , December 2, 2016 Persistence ... pacemaker market in its upcoming report titled, "Global Market Study on ... Declining CAGR of -1.4% between 2016 and 2024". The global ... in 2015 and this is likely to decline to ... the global cardiac pacemaker market is anticipated to exhibit ...
(Date:12/2/2016)... NEW YORK , December 2, 2016 ... Market Research titled "Global Market Study on Automated Endoscope Reprocessors: ... Register a CAGR of 8.6% Between 2016 and 2024 " the ... 2015 and is expected to expand at a CAGR of ... market valuation of US$ 1,367.6 Mn by 2024. ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... ... the launch of its 60-day free trial program for all of the company’s ... the offer a truly hassle free experience. , FlexiSpot’s unique desktop risers use ...
(Date:12/2/2016)... ... December 02, 2016 , ... U.S. Surgeon General, Dr. Vivek Murthy, graces ... explains how he was inspired to practice medicine at an early age by his ... more than making diagnoses and prescribing medicine,” he states. “It is about building relationships ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi Hovsepian, a leading ... the 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The ... education, experience, and professional associations. , One the most frequently honored surgeons ...
(Date:12/2/2016)... ... December 02, 2016 , ... CloudLIMS.com, ... its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and testing ... shipping and disposal. The new version is a faster and a more efficient ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre Springs beneath the ... its unmatched natural purity of just 6 ppm TDS (Total Dissolved Solids) in addition ... has been available in several ShopRite and FoodTown stores in NJ and received rave ...
Breaking Medicine News(10 mins):